(UroToday.com) In this presentation, Dr. Toni Choueiri discussed patient reported outcomes (PROs) from KEYNOTE-564, a randomized phase 3 study of adjuvant Pembrolizumab versus placebo in patients with renal cell carcinoma (RCC). Results of the KEYNOTE-564 trial, initially presented at the ASCO 2021 Annual Meeting and recently published in the New England Journal of Medicine, demonstrated an improvement in disease-free survival at 24 months for patients randomized to receive adjuvant Pembrolizumab (77.3%) versus placebo (68.1%) (HR 0.68, 95% CI 0.53-0.87; P = 0.002).1 Overall survival data was immature and did not cross the pre-specified statistical threshold for this preliminary analysis, but at 24 month trended towards improvement for patients on the Pembrolizumab (96.6%) compared to the placebo (93.5%) arm (HR 0.54, 95% CI 0.30-0.96; P = 0.0164).